Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults

Patricia M. Flynn*, Sharon Nachman, Petronella Muresan, Terence Fenton, Stephen A. Spector, Coleen K. Cunningham, Robert Pass, Ram Yogev, Sandra Burchett, Barbara Heckman, Anthony Bloom, L. Jill Utech, Patricia Anthony, Elizabeth Petzold, Wende Levy, George K. Siberry, Ruth Ebiasah, Judi Miller, Edward Handelsman, Adriana Weinberg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Background. The safety and immunogenicity of high-dose pandemic H1N1 (pH1N1) vaccination in perinatally human immunodeficiency virus type 1 (HIV-1)-infected children, adolescents, and young adults are unknown. Methods. Two 30-g doses of 2009 Novartis pH1N1 monovalent vaccine (Fluvirin) were administered 21-28 days apart to perinatally HIV-1-infected children, adolescents, and young adults. Antibodies were measured by hemagglutination inhibition (HAI) assay at baseline, 21-28 days after first vaccination, 7-13 days after the second vaccination, and 7 months after the first vaccination. Results. Among the 155 participants, 54 were aged 4-8 years, 51 were aged 9-17 years, and 50 were aged 18-24 years. After 2 doses of Fluvirin, seroresponse (≥4-fold rise in HAI titers) was demonstrated in 79.6, 84.8, and 83 of participants in the aforementioned age groups, respectively, and seroprotection (HAI titers ≥40) was shown in 79.6, 82.6, and 85.1, respectively. Of those lacking seroresponse (n = 43) or seroprotection (n = 37) after the first vaccination, 46.5 and 40.5 achieved seroresponse or seroprotection, respectively, after the second vaccination. Among participants who lacked seroprotection at entry, a "complete response" (both seroresponse and seroprotection) after first vaccination was associated with higher baseline log10 HAI titer and non-Hispanic ethnicity. No serious vaccine-related events occurred.Conclusion.Two doses of double-strength pH1N1 vaccine are safe and immunogenic and may provide improved protection against influenza in perinatally HIV-1-infected children and youth. Clinical Trials Registration. NCT00992836.

Original languageEnglish (US)
Pages (from-to)421-430
Number of pages10
JournalJournal of Infectious Diseases
Issue number3
StatePublished - Aug 1 2012

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults'. Together they form a unique fingerprint.

Cite this